Background: The WHO has a list of more than 200 COVID-19 vaccines that are in development. High hopes exist for preventive COVID-19 vaccinations that are successful.3 Vaccines that passed phase III clinical studies and were shown to be safe and efficacious could be available in 2021. A number of vaccines, including Moderna's mRNA-1273 and Pfizer-BioNTech's BNT162b2, have received commercial approval. Both humoral and cellular immunity must be taken into account in the development of the COVID-19 vaccines. Additionally, as COVID-19 is mostly transmitted through touch with the respiratory system, more focus should be placed on the function of mucosal immunity in avoiding viral infections. Four structural proteins are present in the virus.